Financial Review: Tempus AI (NASDAQ:TEM) & Nyxoah (NASDAQ:NYXH)

Tempus AI (NASDAQ:TEM) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Profitability

This table compares Tempus AI and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tempus AI	-22.20%	-53.83%	-11.17%
Nyxoah	-543.21%	-163.73%	-80.24%

Insider & Institutional Ownership

24.2% of Tempus AI shares are held by institutional investors. 24.3% of Tempus AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Tempus AI has a beta of 3.64, meaning that its stock price is 264% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Tempus AI and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempus AI	2	3	9	0	2.50
Nyxoah	1	1	2	0	2.25

Tempus AI presently has a consensus price target of $68.54, indicating a potential upside of 17.54%. Nyxoah has a consensus price target of $7.00, indicating a potential upside of 324.24%. Given Nyxoah’s higher possible upside, analysts clearly believe Nyxoah is more favorable than Tempus AI.

Valuation & Earnings

This table compares Tempus AI and Nyxoah”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempus AI	$1.27 billion	8.23	-$245.03 million	($1.72)	-33.90
Nyxoah	$11.33 million	5.64	-$101.92 million	($2.48)	-0.67

Nyxoah has lower revenue, but higher earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Summary

Tempus AI beats Nyxoah on 11 of the 14 factors compared between the two stocks.

About Tempus AI

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.